RxDoctor Payments Data

Kimberly Ackerman

Adult Health · Billings, MTNPI 1922032861

Payments from drug & device makers

What this record shows

Medtronic accounts for 62.5% of it on its own, with 11 other manufacturers making up the rest.

$2,065in general payments, 2019–2025

Across 32 payments — averaging $64.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Madrigal Pharmaceuticals$205
  • Insulet Corporation$164
  • Lilly USA, LLC$70
  • Novo Nordisk$69
  • Boston Scientific$65
  • plus $203 from 6 others

What the payments were for

  • Travel & lodging$99248%
  • Food & beverage$1,07352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,065 in reported general payments places this provider in the 70th percentile of 27 adult health providers in Montana.

See all adult health providers in Montana

Medicare billing

Part B allowed, 2024
$45,931
Medicare patients
195
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide266$339,165
Tresiba Flextouch U-200Insulin Degludec96$130,746
MounjaroTirzepatide107$117,346
Humulin R U-500 KwikpenInsulin Regular, Human69$111,733
TrulicityDulaglutide64$100,823
Tresiba Flextouch U-100Insulin Degludec126$91,748
JardianceEmpagliflozin110$79,934
Humalog Kwikpen U-200Insulin Lispro11$38,843
RybelsusSemaglutide28$36,661
FarxigaDapagliflozin Propanediol31$36,414
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/733$20,700
JanuviaSitagliptin Phosphate13$19,630
Novolog FlexpenInsulin Aspart63$19,195
FiaspInsulin Aspart (Niacinamide)13$17,613
Fiasp FlextouchInsulin Aspart (Niacinamide)35$16,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$69$405,782361 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$70$227,663237 claims
Boehringer IngelheimJardiance$32$79,934110 claims
Sanofi-aventis U.S. LLCLantus$27$3,46918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 27 adult health providers in Montana.

Other adult health in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →